Improving the Quality of Life of Patients with Arterial Hypertension in Diabetes Mellitus

Kirgizbayeva Aray; Umbetyarova Lyzzat; Bissenbina Gulzhakan; Yessergeneva Riza; S.A. Mankibaeva; S.N. Abdureshov

doi:10.29169/1927-5951.2019.09.02.9

Improving the Quality of Life of Patients with Arterial Hypertension in Diabetes Mellitus

Authors

Kirgizbayeva Aray National Medical University, S. Asfendiyarov
Umbetyarova Lyzzat Kazakh National University, Al Farabi
Bissenbina Gulzhakan National Medical University, S. Asfendiyarov
Yessergeneva Riza National Medical University, S. Asfendiyarov
S.A. Mankibaeva Kazakh National University, Al Farabi
S.N. Abdureshov Laboratory of the Lymph System Physiology, Institute of Human and Animal Physiology SK MES RK, Almaty, Kazakhstan

DOI:

https://doi.org/10.29169/1927-5951.2019.09.02.9

Keywords:

Diabetes mellitus type arterial hypertension self-control blood glucose blood pressure control.

Abstract

Currently, there are no recommendations on the features of detecting early signs of CHF in patients with diabetes mellitus. And they are necessary, taking into account that in case of diabetes mellitus type 2 (more than 95% of all patients with diabetes mellitus), the overwhelming number of patients are overweight and obesity, which can affect the validity of the 6-minute walk test and scale clinical state assessment (SHOX) in the modification.
In the treatment of patients with CHF, the “gold” standard is the use of angiotensin-converting enzyme inhibitors (ACE inhibitors) according to the third edition of the recommendations on the diagnosis and treatment of CHF. Antagonists of receptors for angiotensin II type 1 (APA II) remain at the same time reserve drugs. Adherence to these standards of patients in different regions of the Russian Federation varies over a rather wide range, and there is almost no information about the compliance of patients with diabetes mellitus with prescribed drug therapy in the presence of CHF.
Thus, the need to identify the frequency of CHF in patients with type 2 diabetes, clarifying the features of this diagnosis and optimizing the treatment of such patients is beyond doubt.
Objective: to clarify the frequency of chronic heart failure in patients with type 2 diabetes in the specialized | department of the hospital and unorganized urban population, to assess the adequacy of its diagnosis and treatment.
Research Objectives: Identify the prevalence of chronic heart failure in patients with type 2 diabetes.
To assess the level of diagnosis of chronic heart failure in patients with type 2 diabetes.
To analyze the state of drug therapy for patients with type 2 diabetes in the presence of chronic serum

References

Borovkov NN, Sidorov NV. The relationship of the daily blood pressure profile and heart rate variability in patients with arterial hypertension and insulin dependent diabetes mellitus. Clinic Medicine 2012; 7: 19-21.

Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E. Aldosterone, mortality, acute myocardial infarction or heart failure. Eur Heart J 2012; 33(2): 191-202. https://doi.org/10.1093/eurheartj/ehr176 DOI: https://doi.org/10.1093/eurheartj/ehr176

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patient with left ventricular dysfunction after myocardial infarction. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 2003; 3, 348 (14): 1309-21. DOI: https://doi.org/10.1056/NEJMoa030207

Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M. Obstructive sleep and adrenergic activation in obesity. Mancia Hypertension 2005; 46(2): 321-5. https://doi.org/10.1161/01.HYP.0000174243.39897.6c DOI: https://doi.org/10.1161/01.HYP.0000174243.39897.6c

Schmider R, Rockstroh J, Aepferbacher F. Gender-specific cardiovascular adaptations to essential hypertension. Am J Hypertens 2005; 8: 11601226.

Ohkubo T, Imai Y, Tsuji I. Relation between loss and decline pressure and mortality. The Ohasama Study. Am J Hypertens 2007; 10: 1201-1207. https://doi.org/10.1016/S0895-7061(97)00274-4 DOI: https://doi.org/10.1016/S0895-7061(97)00274-4

Timio M, Venanzi S, LoLLy S, Lippi G. Non-dipper hypertensive patients and progressive renal infsufficiency: a 3 year Long-term study. Clin Nephrol 2005; 43: 382-387.

Brittton SC, Gaziano JM, Djousse L. NormaL systoLic and fayLure in USmaLe physicians. Eur J Heart Fail 2009; 11: 1129-1134. https://doi.org/10.1093/eurjhf/hfp141 DOI: https://doi.org/10.1093/eurjhf/hfp141

KaLaitzidis RG, Bakris GL. Prehypertension: is it reLevant for nephroLogists? Kidney Int 2015; 77: 194-200. DOI: https://doi.org/10.1038/ki.2009.439

Conroy RM, PyoraLa K, FitzgeraLd AP, et al. Estimation of the ten-year risk of cardiovascular disease in Europa: the SCORE project. Eur Heart J 2013; 24: 987-1003. https://doi.org/10.1016/S0195-668X(03)00114-3 DOI: https://doi.org/10.1016/S0195-668X(03)00114-3

Law MR, Morris JK, WaLd NJ. Use of bLood pressure cardiovascuLar disease: Meta-anaLysis of 147 randomized triaLs. BMJ 2009; 338: b1665. https://doi.org/10.1136/bmj.b1665 DOI: https://doi.org/10.1136/bmj.b1665

Verdecchia P, ReboLdi G, AngeLi F, Gattobigio R, BentivogLio M, Thijs L, et al. Angiotensin-Con-verting Enzyme Inhibitors and CaLcium Chanel Blocks for Coronary Heart Disease and Stroke Prevention. Hypertension 2015; 46: 386-392. https://doi.org/10.1161/01.HYP.0000174591.42889.a2 DOI: https://doi.org/10.1161/01.HYP.0000174591.42889.a2

Schmieder RE, HiLgers KF, SchLaich MP, Schmidt BM. Renin-angiotensin system andcardiovascu-Lar risk. Lancet 2007; 369: 1208-1219. https://doi.org/10.1016/S0140-6736(07)60242-6 DOI: https://doi.org/10.1016/S0140-6736(07)60242-6

Kunz R, Friedrich C, Wolbers M, Mann JF. Metaanalysis can be used in combination. Ann Intern Med 2008; 148: 30-48. https://doi.org/10.7326/0003-4819-148-1-200801010-00190 DOI: https://doi.org/10.7326/0003-4819-148-1-200801010-00190

Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. But it wasn’t a great deal of care and attention to patients who have reached a level in the European Lacidipine study at Atherosclerosis (ELSA). Circulation 2009; 120: 1084-1090. https://doi.org/10.1161/CIRCULATIONAHA.108.773119 DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.773119

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent elevatedC-reactive protein. N Engl J Med 2008; 359: 2195-2207. https://doi.org/10.1056/NEJMoa0807646 DOI: https://doi.org/10.1056/NEJMoa0807646

Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circ Res 2008; 62: 1259-12. https://doi.org/10.1161/01.RES.62.6.1259 DOI: https://doi.org/10.1161/01.RES.62.6.1259

Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol 2003; 264(6 pt 1): 1570-1576. DOI: https://doi.org/10.1152/ajpcell.1993.264.6.C1570

Shenoy U, Cassis L. Characterization of brown adipose tissue. Am J Physiol 2007; 272(3 pt 1): 989-999. DOI: https://doi.org/10.1152/ajpcell.1997.272.3.C989

Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Executive summary: Guidelines and guidelines for laboratory diabetes mellitus. Diabetes Care 2011; 34: 1419-23. https://doi.org/10.2337/dc11-9997 DOI: https://doi.org/10.2337/dc11-9997